PBLS

Parabilis Medicines, Inc. PBLS

NasdaqMid CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$148.0K

Quarter to Jun 30

Net income

$-52.46M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.71B total
RA CAPITAL MANAGEMENT, L.P.
$791.91M--
FMR LLC
$281.71M--
ARCH Venture Management, LLC
$175.52M--
venBio Partners LLC
$144.15M--
Alphabet Inc.
$134.65M--
Nextech Invest, Ltd.
$127.63M--
Cormorant Asset Management, LP
$126.33M--
REGENERON PHARMACEUTICALS, INC.
$114.04M--
Siren, L.L.C.
$81.90M--
FARALLON CAPITAL MANAGEMENT LLC
$64.82M--
Jupiter Topco LLC
$62.71M--
Frazier Life Sciences Management, L.P.
$52.57M--
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$51.47M--
General Catalyst Group Management, LLC
$43.82M--
GENERAL ATLANTIC, L.P.
$42.11M--
Soleus Capital Management, L.P.
$40.10M--
VANGUARD PORTFOLIO MANAGEMENT LLC
$35.65M--
VANGUARD CAPITAL MANAGEMENT LLC
$31.67M--
JPMORGAN CHASE & CO
$30.44M--
Foresite Capital Management VI LLC
$27.34M--
Catalio Capital Management, LP
$22.55M--
ALLIANCEBERNSTEIN L.P.
$22.18M--
PRICE T ROWE ASSOCIATES INC /MD/
$20.58M--
Casdin Capital, LLC
$17.67M--
VR Adviser, LLC
$17.11M--
See all 79 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PBLS

Earnings Per Share

13fpro.ai/company/PBLS

Loading ratio trend…

PBLS insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Parabilis Medicines, Inc. (PBLS): stock profile, AI score and financials

Parabilis Medicines, Inc. (PBLS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PBLS is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Parabilis Medicines, Inc. reports quarterly revenue of $148.0K, net income of $-52.5M. Top institutional holders of PBLS by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., FMR, ARCH Venture Management, based on the most recent SEC filings. PBLS trades on the Nasdaq exchange and files with the SEC under CIK 1657677. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PBLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Parabilis Medicines, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1657677 →